Over a median follow-up in responders of 18.0 months (range 15-21), the median duration of complete response was 18.0 months ...
TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...
Safety and efficacy of hepatic artery infusion chemotherapy (HAIC) or lenvatinib combined with sintilimab as neoadjuvant therapy for high recurrence risk resectable stage IB solitary hepatocellular ...
Zacks Small Cap Research on MSN
SNGX: Important upcoming readouts in phase 3 CTCL study
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Important Readouts in 2026 for Phase 3 CTCL Study Soligenix, Inc. (NASDAQ:SNGX) is currently conducting the Phase 3 ...
Hosted on MSN
Viridian Therapeutics’ Veligrotug Shows Durable Proptosis Response in Phase 3 TED Trial
Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the best low priced pharma stocks to buy now. Earlier on May 20, Viridian Therapeutics announced positive long-term durability data from its Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results